In conclusion, after developing the comparative analysis of the current CPGs identified in Latin America with the ADA reference guidelines, multiple information gaps have been found regarding to the recommendations according to the patient profile and the pharmacological management of T2DM, especially in insulin treatment. This evidence concerns the gene INS and type 2 diabetes mellitus.